SARS-CoV-2 (COVID-19) Spike Neutralization Single Domain Antibody [1H12], Unconjugated, Camelus, Monoclonal

Produktübersicht

• Artikelname: SARS-CoV-2 (COVID-19) Spike Neutralization Single Domain Antibody [1H12], Unconjugated, Camelus, Monoclonal
• Artikelnummer: PRS-SD9857
• Hersteller Artikelnummer: SD9857
• Alternativnummer: PRS-SD9857-0.02,PRS-SD9857-0.1
• Hersteller: ProSci
• Wirt: Camelus
• Kategorie: Antikörper
• Applikation: ELISA, NeA
• Spezies Reaktivität: Virus
• Immunogen: SARS-CoV-2 S protein RBD containing C-terminal His Tag. The protein was expressed in human 293 cells (HEK293). It contains amino acids Arg 319 - Lys 537.
• Konjugation: Unconjugated
• Alternative Synonym: SARS-CoV-2 (COVID-19) Spike S1 Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Spike protein, Surface Glycoprotein, covid-19, sars-cov-2

Produkteigenschaften

• Klonalität: Monoclonal
• Konzentration: batch dependent
• Klon-Bezeichnung: [1H12]
• NCBI: 43740568
• UniProt: P0DTC2
• Puffer: SARS-CoV-2 (COVID-19) Spike Neutralization Antibody is supplied in PBS.
• Formulierung: Liquid

Anwendungsbeschreibung

• Application Verdünnung: Optimal dilutions for each application to be determined by the researcher.

Bilder

Figure 1. ACE2-RBD binding inhibition by Antibody SD9857 (1H12).
An ELISA was performed to test whether SARS-CoV-2 (COVID-19) Spike RBD Antibody, SD9857 inhibits the binding of RBD proteins (from the receptor binding domain of the SARS-CoV-2 spike protein wildtype and alpha variant, respectively) to ACE2, a cellular receptor for SARS-CoV-2. The RBD proteins were used as coating antigens at 1 &mu,g/mL. Antibody SD9857 was added at the concentrations indicated followed by the addition of 20 ng/ml human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. SD9857 exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of wild-type and alpha strains.

Figure 2. Pseudovirus neutralization assay with Antibody SD9857 (1H12).
A pseudovirus neutralization assay was performed to test whether SD9857 inhibits the entry of SARS-CoV-2 spike carrying pseudovirus into 293T-hsACE2 cells. The virus-like particles carry a luciferase reporter which can be detected using Promega&rsquo,s Renilla-Glo Luciferase Assay System. Antibody SD9857 was added to the cells at the concentrations indicated together with the virus-like particles. After 72 hrs incubation infectivity was determined by measuring relative light units (RLU) produced by the introduced luciferase reporter. The RLUs obtained with the no-antibody control were set as 100% infectivity, i.e., 0% inhibition). SD9857 exhibited a dose dependent neutralizing effect on the wild-type SARS-CoV-2 pseudovirus.